Skip to main content

Table 2 Clinicopathologic characteristics comparing between responders and non-responders

From: Efficacy of 4′-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study

  Responders Non-responders p value
No. patients 16 10  
Sex, male 14 9 1.00
Mean age years (standard deviation) 65.2 (10.7) 71.6 (4.9) 0.072
Location 0.17
 Upper 3 4
 Middle 8 6
 Lower 5 0
Clinical T-stage 0.141
 cT2 1 1
 cT3 6 7
 cT4 9 2
Clinical N-stage 0.090
 cN0 1 5
 cN1 4 2
 cN2 10 3
 cN3 1 0
Neoadjuvant therapy 0.051
 Chemotherapy 6 8
 Chemoradiation therapy 10 2
Tumor marker
 SCC (ng/mL) [median (range)] 1.9 (0.7–6.2) 2.8 (0.6–8.1) 0.36
 CEA (ng/mL) [median (range)] 2.4 (0.6–6.4) 2.1 (0.2–8.6) 0.90